EXPRES2ION BIOTECH HOLDING AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.545 SEK | -2.12% |
|
-8.45% | +20.62% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 300.9 | 1,145 | 621.6 | 130.8 | 130.8 | - |
| Enterprise Value (EV) 1 | 300.9 | 1,008 | 512.4 | 51.14 | 127.2 | 170.2 |
| P/E ratio | -5.92 x | -24.5 x | -4.89 x | -1.01 x | -2.61 x | -3.27 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 83.4 x | 101 x | 12.3 x | 15.4 x | 15.4 x |
| EV / Revenue | - | 73.4 x | 83.3 x | 5.81 x | 15 x | 20 x |
| EV / EBITDA | - | -21.6 x | -4.05 x | -0.49 x | -2.54 x | -4.26 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | 8.16 x | 5.61 x | 1.78 x | 34.9 x | -3.6 x |
| Nbr of stocks (in thousands) | 27,608 | 31,153 | 37,607 | 51,405 | 51,405 | - |
| Reference price 2 | 10.90 | 36.76 | 16.53 | 2.545 | 2.545 | 2.545 |
| Announcement Date | 2/25/21 | 2/24/22 | 2/9/23 | 2/8/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 13.73 | 6.15 | 8.799 | 8.5 | 8.5 |
| EBITDA 1 | - | -46.59 | -126.4 | -104.4 | -50 | -40 |
| EBIT 1 | - | -48.4 | -127.6 | -106 | -50 | -40 |
| Operating Margin | - | -352.48% | -2,074.89% | -1,204.28% | -588.24% | -470.59% |
| Earnings before Tax (EBT) 1 | - | -47.52 | -126.6 | -104.6 | -50.04 | -40.04 |
| Net income 1 | -31.99 | -43.92 | -118.6 | -95.99 | -50.04 | -40.04 |
| Net margin | - | -319.92% | -1,928.54% | -1,090.91% | -588.7% | -471.01% |
| EPS 2 | -1.840 | -1.500 | -3.380 | -2.080 | -0.9734 | -0.7788 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 2/25/21 | 2/24/22 | 2/9/23 | 2/8/24 | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 39.4 |
| Net Cash position 1 | - | 137 | 109 | 57.3 | 3.63 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.9852 x |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 4.510 | 2.940 | 1.190 | 0.0700 | -0.7100 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 2/25/21 | 2/24/22 | 2/9/23 | 2/8/24 | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.545
SEK
Average target price
9
SEK
Spread / Average Target
+253.63%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +20.62% | 11.91M | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.98% | 31.28B | |
| +57.86% | 25.27B | |
| -16.24% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| -17.10% | 11.69B | |
| +6.89% | 8.83B |
- Stock Market
- Equities
- EXPRS2 Stock
- Financials ExpreS2ion Biotech Holding AB
